Dipexium’s and Innocoll’s Antibacterial Candidates for Diabetic Foot Infection Flop in Q4 of 2016

  • RSS Feed

Diabetic foot infections (DFIs) are a common complication of diabetic foot ulcers (DFUs), with an estimated prevalence of 58% among all diagnosed DFU patients. If left untreated, DFIs can cause osteomyelitis, severe sepsis, and a risk of amputation. Ischemic and chronic ulcers carry an increased risk of infections that are composed of multiple bacterial species, along with an increased risk of these polymicrobial communities displaying reduced susceptibility towards multiple antibiotics. Despite the availability of various antibiotics, including Pfizer’s Zyvox (linezolid) and Merck’s Invanz (ertapenem), both indicated for DFIs, there remains the need for additional therapies to help address hard-to-treat DFIs. In an attempt to meet this unmet need, Dipexium Pharmaceuticals and Innocoll were developing two topical antibacterial candidates, Locilex (pexiganan) and Cogenzia (gentamicin-collagen sponge), respectively.

Gain full access to this article

You must register to read the full Expert Insight article. Register for FREE today and access all our healthcare Expert Insights.


Registering for our Expert Insights is free and only takes a moment.

Following this you'll gain unlimited access to all of the latest, event-driven opinion put together by our teams of experienced analysts.

Send to a colleague


© GlobalData 2017. John Carpenter House, 7 Carmelite Street, London EC4 0BS.